Assenagon Asset Management S.A. Makes New $8.16 Million Investment in Sarepta Therapeutics, Inc. $SRPT

Key Points

• Assenagon Asset Management purchased 454,375 Sarepta Therapeutics shares worth approximately $8.16 million, giving it a roughly 0.43% stake.
• Institutional investors and hedge funds own approximately 86.68% of SRPT, with several firms recently increasing their positions.
• Analyst sentiment remains mixed: the stock carries a consensus “Hold” rating and a $25.06 price target, while SRPT recently opened at $18.22 after trading between $14.68 and $25.32 over the past year.

Assenagon Asset Management S.A. purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 454,375 shares of the biotechnology company's stock, valued at approximately $8,165,000. Assenagon Asset Management S.A. owned approximately 0.43% of Sarepta Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of SRPT. Yousif Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 1.9% in the 4th quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company's stock valued at $541,000 after acquiring an additional 481 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Sarepta Therapeutics by 7.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company's stock worth $190,000 after purchasing an additional 636 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in Sarepta Therapeutics by 3.3% during the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company's stock worth $396,000 after purchasing an additional 744 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Sarepta Therapeutics by 1.8% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company's stock worth $829,000 after purchasing an additional 758 shares during the period. Finally, Larson Financial Group LLC grew its holdings in Sarepta Therapeutics by 82.5% during the fourth quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 851 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Wall Street Analysts Forecast Growth

SRPT has been the topic of a number of recent analyst reports. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating on the stock in a research report on Thursday, July 9th. Zacks Research lowered shares of Sarepta Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, July 7th. Weiss Ratings downgraded shares of Sarepta Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a report on Wednesday, August 5th. Wolfe Research raised shares of Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research report on Thursday, July 9th. Finally, HC Wainwright restated a "buy" rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Nine equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and six have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $25.06.

Sarepta Therapeutics Stock Performance

SRPT opened at $18.22 on Wednesday. The stock has a market cap of $1.92 billion, a PE ratio of -6.28, a P/E/G ratio of 0.22 and a beta of 0.23. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics, Inc. has a 1 year low of $14.68 and a 1 year high of $25.32. The stock's 50 day simple moving average is $16.95 and its 200-day simple moving average is $18.44.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source